Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Femasys Inc
(NQ:
FEMY
)
1.270
-0.020 (-1.55%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Femasys Inc
< Previous
1
2
Next >
Femasys Inc. Obtains Medical Device Establishment License from Health Canada
August 31, 2023
From
Femasys Inc.
Via
GlobeNewswire
Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update
August 10, 2023
From
Femasys Inc.
Via
GlobeNewswire
Femasys Initiates Enrollment in Pivotal Trial of its Permanent Birth Control Candidate FemBloc
August 03, 2023
- First of its kind, non-surgical, permanent birth control option begins enrollment in landmark trial -
From
Femasys Inc.
Via
GlobeNewswire
Femasys Announces FDA Approval of its IDE for the Pivotal Clinical Trial of FemBloc Permanent Birth Control, a Non-Surgical Alternative for Women
June 26, 2023
From
Femasys Inc.
Via
GlobeNewswire
Femasys Inc. Replaces Two Board Members with Seasoned Industry Leaders in the Life Sciences
June 15, 2023
From
Femasys Inc.
Via
GlobeNewswire
Femasys to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on June 20-22, 2023
June 14, 2023
From
Femasys Inc.
Via
GlobeNewswire
Femasys’ FemCath Intrauterine Catheter Receives Product Approval in Canada
June 08, 2023
From
Femasys Inc.
Via
GlobeNewswire
Femasys Inc. Announces Financial Results for the First Quarter Ended March 31, 2023
May 11, 2023
From
Femasys Inc.
Via
GlobeNewswire
Femasys Inc. to Showcase Four Products at the American College of Obstetricians and Gynecologists Annual Clinic & Scientific Meeting
May 11, 2023
From
Femasys Inc.
Via
GlobeNewswire
Femasys’ FemCerv Endocervical Tissue Sampler for Cervical Cancer Diagnosis Receives Product Approval in Canada
May 03, 2023
From
Femasys Inc.
Via
GlobeNewswire
Femasys Inc. to Showcase FemCerv at the Annual Meeting for the American Society for Colposcopy and Cervical Pathology
May 01, 2023
From
Femasys Inc.
Via
GlobeNewswire
Femasys Announces $3.9 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
April 19, 2023
From
Femasys Inc.
Via
GlobeNewswire
Femasys’ FemaSeed Localized Directional Insemination for Infertility Receives Product Approval in Canada
April 18, 2023
From
Femasys Inc.
Via
GlobeNewswire
Femasys Inc. Announces Financial Results for the Year Ended December 31, 2022 and Provides Corporate Update
March 30, 2023
From
Femasys Inc.
Via
GlobeNewswire
Femasys Inc. to Participate in “The Post-Roe Fertility Journey” Panel Discussion at SXSW 2023
March 09, 2023
From
Femasys Inc.
Via
GlobeNewswire
Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2022 and Provides Corporate Update
November 10, 2022
From
Femasys Inc.
Via
GlobeNewswire
Femasys Inc. Announces Enrollment Completion for Stage 2 Study of FemBloc for Permanent Birth Control
October 06, 2022
Company remains on track to file an investigational device exemption (IDE) for a pivotal trial to support a pre-market authorization (PMA) in the first quarter of 2023
From
Femasys Inc.
Via
GlobeNewswire
Femasys Inc. Announces the Commercial Availability of FemCerv® for Cervical Cancer Screening and Expands Management Team
September 29, 2022
From
Femasys Inc.
Via
GlobeNewswire
IPO Launch: 31.6 Million Dollar Raised; Clinical Trials Underway on Key Female Oriented Healthcare Advances: Femasys (NASDAQ: FEMY)
August 31, 2021
Via
Get News
Topics
Initial Public Offering
Exposures
Securities Market
Clinical Trials Underway on Key Female Oriented Healthcare Advances from new IPO Launch: Femasys (NASDAQ: FEMY)
July 19, 2021
Via
Get News
Topics
Initial Public Offering
Exposures
Securities Market
Woman-Lead BioPharma Starts Clinical Trials on Key Female Oriented Healthcare Advances: Femasys (NASDAQ: FEMY)
July 06, 2021
Via
Get News
Topics
Initial Public Offering
Exposures
Securities Market
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.